Save
esh.org
From MGUS to MM: Do all clones take the same road?
ESH eLearning, Madhav Dhodapkar, 233965
Leukemic stem cells modulate the bone marrow microenvironment
ESH eLearning, María-Victoria Mateos, 233966
Genetics and risk assessment (including clonal evolution and clinical implications in terms of risk assessment)
ESH eLearning, Hervé Avet-Loiseau, 233967
Primary plasma cell leukaemia and extramedullary disease
ESH eLearning, Niels VAN DE DONK, 233968
Geriatric assessment: is it required?
ESH eLearning, Alessandra Larocca, 233969
European guidelines
ESH eLearning, Sonja ZWEEGMAN, 233970
Ongoing trials for newly diagnosed patients not eligible for stem cell transplantation, and frontline treatment when new drugs are not available
ESH eLearning, Kwee Yong, 233971
Induction therapy: triplet, quadruplet?
ESH eLearning, Philippe Moreau, 233972
Geriatric assessment in multiple myeloma: is it required?
ESH eLearning, Alessandra Larocca, 234000
MRD as a response assessment in elderly multiple myeloma
ESH eLearning, Alessandra Larocca, 234001
Vaccines to prevent progression or relapse in multiple myeloma
ESH eLearning, Ann van de Velde, 234002
How do we define a ‘cure’ in myeloma?
ESH eLearning, Annemiek Broijl, 234003
Treatment options for high-risk myeloma
ESH eLearning, Annemiek Broijl, 234004
Smoldering myeloma treatment landscape & MRD negativity
ESH eLearning, Annemiek Broijl, 234005
Real world data: bortezomib-based therapy for R/R myeloma
ESH eLearning, Evangelos Terpos, 234014
Real world data for len/dex in second-line myeloma: what does this tell us?
ESH eLearning, Evangelos Terpos, 234015
Double-blind trial of denosumab vs. zoledronic acid for bone disease in NDMM
ESH eLearning, Evangelos Terpos, 234016
Treatment sequencing in multiple myeloma: a multitude of options
ESH eLearning, Heinz Ludwig, 234017
Emerging treatments for myeloma: quadruplets, bispecific antibodies & CAR T-cells
ESH eLearning, Heinz Ludwig, 234018
Smoldering multiple myeloma: what is the current definition & new screening programme
ESH eLearning, Irene Ghobrial, 234019
Opinion: MRD sequencing test approval in multiple myeloma
ESH eLearning, Irene Ghobrial, 234020
CAR T-cells for multiple myeloma: update & what's in store for ASH 2018
ESH eLearning, Jesus Berdeja, 234021
Real world evidence: what is it and what can it tell us?
ESH eLearning, Kwee Yong, 234030
How should smoldering multiple myeloma be monitored?
ESH eLearning, María-Victoria Mateos, 234031
Update on recent smoldering multiple myeloma trials
ESH eLearning, María-Victoria Mateos, 234032
Updated CASTOR analysis: daratumumab plus Vd for R/R myeloma
ESH eLearning, María-Victoria Mateos, 234033
Opinion: EU approval of daratumumab plus VMP for frontline transplant-ineligible multiple myeloma
ESH eLearning, María-Victoria Mateos, 234034
Plasma cell leukemia and extramedullary disease in multiple myeloma
ESH eLearning, Niels van de Donk, 234035
Daratumumab in myeloma update: expanding indications
ESH eLearning, Niels van de Donk, 234036
A novel mechanism of action for daratumumab in myeloma
ESH eLearning, Niels van de Donk, 234037
Precision medicine in multiple myeloma: BRAF, NRAS, KRAD, t(11;14)
ESH eLearning, Noopur Raje, 234046
Judging the value of a clinical trial in hem-onc
ESH eLearning, Robert Hills, 234047
Opinion: value of MRD as an endpoint in hem-onc clinical trials
ESH eLearning, Robert Hills, 234048
UK NCRI AML17 trial update: everolimus addition for consolidation
ESH eLearning, Robert Hills, 234049
Monoclonal antibodies: current and future potential
ESH eLearning, Saad Usmani, 234050
Targeting BCMA with bispecific antibodies in R/R myeloma
ESH eLearning, Saad Usmani, 234051
Updated POLLUX results for early relapsed myeloma patients
ESH eLearning, Saad Usmani, 234052
Whole genome sequencing opens door for targeted Waldenström’s therapy
ESH eLearning, Steve Treon, 234053
How to predict response in silico and in vitro?
ESH eLearning, David Weinstock, 234062
Design of innovative clinical trials: still a role for phase III trials?
ESH eLearning, Andrew Davies, 234063
Minimal biological measurement requirements for DLBCL: What do clinicians need to have measured?
ESH eLearning, Lisa RIMSZA, 234061
Rational Targeting of the NuRD Complex For Fetal Hemoglobin Induction 2019 ESH Erythropoiesis
ESH eLearning, Daniel E. Bauer, 265280
Fanconi anaemia
ESH eLearning, Carlo Dufour, 265281
Autoimmune haemolytic anaemias
ESH eLearning, Wilma Barcellini, 265282
Inflammation as a determinant of ineffective erythropoiesis in myelodysplastic syndromes
ESH eLearning, Alan List, 265283
TGF-b pathway inhibitors in low risk MDS
ESH eLearning, Valeria Santini, 265284
New approches to managing sickle cell disease
ESH eLearning, David Rees, 265285
Heme regulation and GATA1
ESH eLearning, Janis Abkowitz, 265286
Gene editing for thalassemia and sickle cell disease
ESH eLearning, Daniel E. Bauer, 265287
Gene therapy for thalassaemia / sickle cell disease
ESH eLearning, Alexis A. Thompson, 265288
Diamond-Blackfan anaemia : genetic and clinical complexity exemplified by 3 cases encountered in clinical practice
ESH eLearning, Marcin Wlodarski, 265289
Which pro-survival BCL-2 family member should be targeted for the treatment of which type of leukaemia or lymphoma
ESH eLearning, Andreas STRASSER, 234057
Targeting MALT1 signaling: preclinical data and perspectives in the clinic
ESH eLearning, Daniel KRAPMANN, 234058
The genetic landscape of MCL – more than CyclinD1?
ESH eLearning, Eias CAMPO, 234059
T-NHL: novel targets and therapies - How can we move forward?
ESH eLearning, Norbert SCHMITZ, 234060
Origin of mega/erythroid progenitors in haematopoiesis
ESH eLearning, Claus Nerlov, 265270
Transcription Factors in Erythropoiesis
ESH eLearning, John Strouboulis, 265271
Congenital dyserythropoietic anaemias (CDAs)
ESH eLearning, Achille Iolascon, 265272
Congenital dyserythropoietic anaemias
ESH eLearning, Roberta Russo, 265273
Clinical consequences of ineffective erythropoiesis in myelodysplastic syndromes
ESH eLearning, Aristoteles Giagounidis, 265274
Hereditary haemolytic anaemias
ESH eLearning, Immacolata Andolfo, 265275
Sickle cell disease
ESH eLearning, Mariane de Montalembert, 265276
Acute sickling crisis
ESH eLearning, Lucia De Franceschi, 265277
The relationship between genome structure and function : lessons from the globin loci
ESH eLearning, Douglas Higgs, 265278
Promoter mutations associated with hereditary persistence of fetal haemoglobin either disrupt repressors or create de novo sites for activators
ESH eLearning, Merlin Crossley, 265279
Managing CML in emerging regions: some problems and perspectives
ESH eLearning, Hemant Malhotra, 234664
Long-term survival of patients with chronic phase chronic myeloid leukemia who received autologous stem cell transplantation and further exposed to tyrosine kinase inhibitors
ESH eLearning, Mauricette Michallet, 234801
The technical decline in the rate of CML treatment-free remission in aging countries: the French experience
ESH eLearning, Marc Delord, 257017
Prevalence and outcomes of uncommon BCR-ABL fusion transcripts in patients with CML: data from a single center
ESH eLearning, Qian Jiang, 257018
Aim for the cure: TKI-based chemotherapy for Ph+ ALL
ESH eLearning, Elias Jabbour, 257019
Patients' perspectives on the definition of cure in chronic myeloid leukemia: a US based survey
ESH eLearning, Gemlyn George, 257030
Long-term results of a phase 2 trial of nilotinib 400 Mg twice daily in newly diagnosed patients with chronic phase of chronic myeloid leukemia
ESH eLearning, Lucia Masarova, 257031
Treatment-free remission in patients with chronic phase chronic myeloid leukemia and stable deep molecular response discontinuing dasatinib (DASFREE)
ESH eLearning, Susanne Saussele, 257032
Low-intensity TKI-based therapy for Ph+ ALL
ESH eLearning, Hervé Dombret, 234568
Impact of kinase domain mutations on second line nilotinib therapy In CML chronic phase – Real world data from a developing country perspective
ESH eLearning, Shinto Francis Thekkudan, 234569
Are TKI really safe?
ESH eLearning, C Gambacorti, 234570
Long-term impact of early and deeper molecular response in newly diagnosed CML-CP patients receiving radotinib: three years follow-up of rerise study
ESH eLearning, Young Rok Do, 234571
Molecular milestones using the BCR-ABL1 qPCR level and doubling time after imatinib discontinuation to predict successful treatment-free remission: treatment-free remission accomplished by dasatinib (TRAD) trial
ESH eLearning, Dennis KIM, 234573
Stem cell transplant for Ph+ ALL: who, when, how
ESH eLearning, Federico Lussana, 234797
How to identify and manage Ph-like ALL
ESH eLearning, Sarah Tasian, 234798
What prevents the disease from relapsing after TKI discontinuation
ESH eLearning, Satu Mustjoki, 234803
Loss of function of the SETD2 tumor suppressor is a recurrent event in advanced-phase chronic myeloid leukemia, is due to post-translational mechanisms and fosters genetic instability
ESH eLearning, Manuela Mancini, 257025
MDS/MPN: SENECTUS IPSA EST MORBUS?
ESH eLearning, Michael Deininger, 257026
CML hematopoietic stem cells expressing IL-1RAP may be targets of chimeric antigen receptor (CAR) - engineered T-cells
ESH eLearning, Christophe Ferrand, 257027
A genome-scale CRISPR knock-out screen in chronic myeloid leukemia identifies common drug resistance mechanisms 
ESH eLearning, Matthieu Lewis, 257028
Modulation of p53 with the MDM2 antagonist idasanutlin, in combination with nilotinib treatment, targets primitive CML cells in vitro and in vivo.
ESH eLearning, David Vetrie, 257029
ELN and real-word treatment algorithms for MPNs
ESH eLearning, Giuseppe Saglio, 234566
The association of transposable elements with chronic myeloid leukemia supports an assumption that non-coding variable regions of the human genome may play a role in hematological malignancies
ESH eLearning, Jitka Koblihova, 234567
HMGCLL1 Is a predictive germline biomarker for deep molecular response to imatinib therapy in chronic myeloid leukemia
ESH eLearning, Dennis KIM, 234572
Bcl-2 and its inhibition in leukemia
ESH eLearning, Marina Konopleva, 234637
Novel approaches to monitor MPN
ESH eLearning, Jerry Radich, 234799
Resistance and progression to TKI: not just mutations
ESH eLearning, Jerry Radich, 234800
Single-molecule sequencing reveals patterns of pre-existing drug resistance that suggest treatment strategies in Philadelphia-positive leukemias
ESH eLearning, Justin Pritchard, 234802
Nilotinib vs. Nilotinib plus interferon α induction and nilotinib or interferon α maintenance therapy for newly diagnosed BCR-ABL positive. Chronic myeloid leukemia patients in chronic phase: interim analysis of the tiger (CML V) trial
ESH eLearning, Andreas Hochhaus, 257020
Spirit 2: final analysis of an NCRI randomised study comparing dasatinib with imatinib in patients with newly diagnosed CML
ESH eLearning, Stephen OBrien, 257021
TNFα-induced bone marrow stromal niche alterations enhance leukemic stem cell growth via CXCL1/CXCR2 signaling
ESH eLearning, Puneet Agarwal, 257022
Identification of metabolic vulnerabilities in leukemic stem cells using the integrative omic approach 
ESH eLearning, Zuzana Brabcova, 257023
Minimal, measurable, atypical
ESH eLearning, Nick Cross, 257024
Why the fuss over CML stem cells ?
ESH eLearning, Robert Peter Gale, 234565
Mastocytosis
ESH eLearning, Jason Gotlib, 219417

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.


Save Settings